$ANIP
ANI PHARMACEUTICALS INC Stock $anip

$anip Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-K Financial Statement

#000114420417012507 Filed on March 02, 2017

Income Statement

Concept	2015 Q4	2015 Q3	2015 Q2
Revenue	$18.04M	$19.97M	$19.52M
YoY Change	-14.27%	14.87%	193.61%
Cost Of Revenue	$3.540M	$3.260M	$3.141M
YoY Change	-3.54%	6.5%	48.37%
Gross Profit	$14.50M	$16.71M	$16.38M
YoY Change	-16.47%	16.66%	261.48%
Gross Profit Margin	80.4%	83.68%	83.91%
Selling, General & Admin	$5.460M	$5.399M	$5.551M
YoY Change	15.19%	33.08%	2.17%
% of Gross Profit	37.66%	32.31%	33.9%
Research & Development	$660.0K	$815.0K	$995.0K
YoY Change	15.79%	-7.7%	16.92%
% of Gross Profit	4.55%	4.88%	6.08%
Depreciation & Amortization	$2.110M	$2.047M	$1.415M
YoY Change	64.84%	72.45%	100.42%
% of Gross Profit	14.55%	12.25%	8.64%
Operating Expenses	$8.230M	$6.214M	$6.546M
YoY Change	24.7%	25.79%	4.17%
Operating Profit	$6.268M	$8.451M	$8.414M
YoY Change	-41.81%	3.07%	-442.03%
Interest Expense	-$2.770M	-$2.766M	-$2.749M
YoY Change	246.25%	-27760.0%	-91733.33%
% of Operating Profit	-44.19%	-32.73%	-32.67%
Other Income/Expense, Net	$0.00	-$28.00K	$0.00
YoY Change	-100.0%	-134.15%	-100.0%
Pretax Income	$3.500M	$5.657M	$5.665M
YoY Change	-65.21%	-31.77%	-326.96%
Income Tax	$630.0K	$1.098M	$2.094M
% Of Pretax Income	18.0%	19.41%	36.96%
Net Earnings	$2.880M	$4.559M	$3.571M
YoY Change	-86.29%	-32.42%	-251.12%
Net Earnings / Revenue	15.97%	22.83%	18.3%
Basic Earnings Per Share	$0.25	$0.40	$0.31
Diluted Earnings Per Share	$0.25	$0.39	$0.31
COMMON SHARES
Basic Shares Outstanding		11.38M shares	11.34M shares
Diluted Shares Outstanding			11.55M shares

Balance Sheet

Concept	2015 Q4	2015 Q3	2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$154.7M	$150.9M	$166.7M
YoY Change	-8.46%	329.91%	214.53%
Cash & Equivalents	$154.7M	$150.9M	$166.7M
Short-Term Investments
Other Short-Term Assets	$1.500M	$10.30M	$9.600M
YoY Change	36.36%	1616.67%	1820.0%
Inventory	$13.39M	$13.70M	$12.70M
Prepaid Expenses	$1.453M	$1.985M	$1.615M
Receivables	$21.93M	$21.60M	$18.88M
Other Receivables	$1.200M	$1.000M	$1.000M
Total Short-Term Assets	$192.6M	$197.5M	$208.9M
YoY Change	-1.23%	243.13%	210.93%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.131M	$5.833M	$5.249M
YoY Change	36.53%	15.6%	14.11%
Goodwill	$1.838M		$1.838M
YoY Change	0.0%
Intangibles	$66.40M		$44.17M
YoY Change	57.84%
Long-Term Investments
YoY Change
Other Assets	$17.30M	$9.800M	$9.900M
YoY Change	12.34%
Total Long-Term Assets	$92.68M	$85.78M	$61.17M
YoY Change	34.87%	71.31%	116.93%
TOTAL ASSETS
Total Short-Term Assets	$192.6M	$197.5M	$208.9M
Total Long-Term Assets	$92.68M	$85.78M	$61.17M
Total Assets	$285.3M	$283.3M	$270.1M
YoY Change	8.17%	163.2%	183.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.066M	$2.600M	$1.325M
YoY Change	-22.16%	-15.0%	-22.06%
Accrued Expenses	$617.0K	$2.221M	$3.900M
YoY Change	-51.38%	-42.88%	254.55%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.76M	$12.19M	$6.949M
YoY Change	-11.16%	49.66%	82.87%
LONG-TERM LIABILITIES
Long-Term Debt	$113.4M	$115.2M	$113.7M
YoY Change	6.48%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$113.4M	$115.2M	$113.7M
YoY Change	6.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.76M	$12.19M	$6.949M
Total Long-Term Liabilities	$113.4M	$115.2M	$113.7M
Total Liabilities	$125.2M	$127.4M	$120.6M
YoY Change	4.52%	1472.63%	3074.24%
SHAREHOLDERS EQUITY
Retained Earnings	-$4.350M	-$7.226M	-$11.79M
YoY Change	-77.95%	-82.26%
Common Stock	$1.000K	$1.000K	$1.000K
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$0.00	$113.0K
YoY Change
Treasury Stock Shares		0.000 shares	4.892K shares
Shareholders Equity	$160.1M	$155.9M	$149.5M
YoY Change
Total Liabilities & Shareholders Equity	$285.3M	$283.3M	$270.1M
YoY Change	9.9%	163.18%	183.08%

Cashflow Statement

Concept	2015 Q4	2015 Q3	2015 Q2
OPERATING ACTIVITIES
Net Income	$2.880M	$4.559M	$3.571M
YoY Change	-86.29%	-32.42%	-251.12%
Depreciation, Depletion And Amortization	$2.110M	$2.047M	$1.415M
YoY Change	64.84%	72.45%	100.42%
Cash From Operating Activities	$4.700M	$10.23M	$1.210M
YoY Change	-56.24%	145.91%	-37.95%
INVESTING ACTIVITIES
Capital Expenditures	-$1.100M	-$770.0K	$4.300M
YoY Change	223.53%	87.8%	-1820.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$26.00M	-$4.500M
YoY Change		17.59%
Cash From Investing Activities	-$1.100M	-$26.77M	-$200.0K
YoY Change	233.33%	18.82%	-20.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	180.0K	710.0K	160.0K
YoY Change	-99.85%	54.35%	-245.45%
NET CHANGE
Cash From Operating Activities	4.700M	10.23M	1.210M
Cash From Investing Activities	-1.100M	-26.77M	-200.0K
Cash From Financing Activities	180.0K	710.0K	160.0K
Net Change In Cash	3.780M	-15.83M	1.170M
YoY Change	-97.18%	-11.61%	-26.42%
FREE CASH FLOW
Cash From Operating Activities	$4.700M	$10.23M	$1.210M
Capital Expenditures	-$1.100M	-$770.0K	$4.300M
Free Cash Flow	$5.800M	$11.00M	-$3.090M
YoY Change	-47.65%	140.7%	-240.45%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-11327000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	20079000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	5002000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	625000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	3934000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2906000	USD
CY2016	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	27829000	USD
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	22343000	USD
CY2016	us-gaap	Costs And Expenses CostsAndExpenses	108543000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	8678000	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4744000	USD
CY2016	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.34
CY2016	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.34
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11445000	shares
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11573000	shares
CY2014	us-gaap	Revenues Revenues	55970000	USD
CY2016Q4	anip	Returned Goods Reserve ReturnedGoodsReserve	5756000	USD
CY2015Q4	anip	Returned Goods Reserve ReturnedGoodsReserve	2648000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	31948000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11756000	USD
CY2016Q4	anip	Class C Special Stock Value ClassCSpecialStockValue	0	USD
CY2015Q4	anip	Class C Special Stock Value ClassCSpecialStockValue	0	USD
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Liabilities Liabilities	153216000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	125183000	USD
CY2016Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	120643000	USD
CY2015Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	113427000	USD
CY2015Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	606000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	0	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	0	USD
CY2015	us-gaap	Revenues Revenues	76322000	USD
CY2015	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21156000	USD
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6900000	USD
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11557000	shares
CY2015	us-gaap	Costs And Expenses CostsAndExpenses	43622000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	32700000	USD
CY2015	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-11008000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	15375000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	21733000	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6358000	USD
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.34
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.32
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11370000	shares
CY2014	us-gaap	Cost Of Revenue CostOfRevenue	11473000	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2678000	USD
CY2016	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	7281000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	20006000	USD
CY2014	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-787000	USD
CY2014	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3300000	USD
CY2015	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6200000	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-127319000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	169037000	USD
CY2016	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	4312000	USD
CY2016	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	6372000	USD
CY2016	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	844000	USD
CY2016	us-gaap	Interest Costs Capitalized Adjustment InterestCostsCapitalizedAdjustment	234000	USD
CY2016	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	144494000	USD
CY2015	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	30500000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4566000	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2183000	USD
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1570000	USD
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	819000	USD
CY2014	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	17935000	USD
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3878000	USD
CY2014	us-gaap	Costs And Expenses CostsAndExpenses	35964000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	28747000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	19379000	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-9368000	USD
CY2014	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.61
CY2014	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.59
CY2014	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10941000	shares
CY2014	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11053000	shares
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-74000	USD
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	41000	USD
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	160000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	6067000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	3856000	USD
CY2015	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	6831000	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	23963000	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4635000	USD
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1938000	USD
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5869000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	647000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	314000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1076000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1027000	USD
CY2016	anip	Increase Decrease In Accrued Compensation Liabilities IncreaseDecreaseInAccruedCompensationLiabilities	443000	USD
CY2015	anip	Increase Decrease In Accrued Compensation Liabilities IncreaseDecreaseInAccruedCompensationLiabilities	-160000	USD
CY2016	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	3525000	USD
CY2015	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	-5380000	USD
CY2016	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	940000	USD
CY2015	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	90000	USD
CY2016	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	617000	USD
CY2015	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	360000	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-14353000	USD
CY2016	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	9537000	USD
CY2015	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	13255000	USD
CY2016	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	247000	USD
CY2015	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	439000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	27472000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	17264000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-154062000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-32683000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-729000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1066000	USD
CY2016	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2500000	USD
CY2015	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2016	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	6269000	USD
CY2015	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	-96000	USD
CY2016	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	5002000	USD
CY2015	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2016	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	294000	USD
CY2015	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2016	anip	Payment For Treasury Stock Purchases For Restricted Stock Vestings And Forfeitures PaymentForTreasuryStockPurchasesForRestrictedStockVestingsAndForfeitures	122000	USD
CY2015	anip	Payment For Treasury Stock Purchases For Restricted Stock Vestings And Forfeitures PaymentForTreasuryStockPurchasesForRestrictedStockVestingsAndForfeitures	113000	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	3423000	USD
CY2014	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	559000	USD
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4784000	USD
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3468000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	558000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	225000	USD
CY2014	anip	Increase Decrease In Accrued Compensation Liabilities IncreaseDecreaseInAccruedCompensationLiabilities	575000	USD
CY2014	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	4233000	USD
CY2014	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	240000	USD
CY2014	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	34634000	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1120000	USD
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	819000	USD
CY2014	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	784000	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	157932000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11105000	USD
CY2014	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	147000	USD
CY2014	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	22033000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-35754000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	171653000	USD
CY2014	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2014	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	702000	USD
CY2014	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2014	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2014	anip	Payment For Treasury Stock Purchases For Restricted Stock Vestings And Forfeitures PaymentForTreasuryStockPurchasesForRestrictedStockVestingsAndForfeitures	0	USD
CY2016Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	143750000	USD
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	20644000	USD
CY2016Q4	us-gaap	Long Term Debt LongTermDebt	120643000	USD
CY2015Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	143750000	USD
CY2015Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	27016000	USD
CY2015Q4	us-gaap	Long Term Debt LongTermDebt	113427000	USD
CY2016Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	2463000	USD
CY2015Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	3307000	USD
CY2015	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	4312000	USD
CY2015	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	6043000	USD
CY2015	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	844000	USD
CY2015	us-gaap	Interest Costs Capitalized Adjustment InterestCostsCapitalizedAdjustment	56000	USD
CY2016Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	14138000	USD
CY2015Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	10192000	USD
CY2016Q4	us-gaap	Retail Related Inventory Packaging And Other Supplies RetailRelatedInventoryPackagingAndOtherSupplies	930000	USD
CY2015Q4	us-gaap	Retail Related Inventory Packaging And Other Supplies RetailRelatedInventoryPackagingAndOtherSupplies	998000	USD
CY2016Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	10812000	USD
CY2015Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1897000	USD
CY2016Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	174000	USD
CY2015Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	156000	USD
CY2016Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	477000	USD
CY2015Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	456000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5387000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4450000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	20894000	USD
CY2016	us-gaap	Depreciation Depreciation	900000	USD
CY2015	us-gaap	Depreciation Depreciation	700000	USD
CY2014	us-gaap	Depreciation Depreciation	600000	USD
CY2016	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	200000	USD
CY2015	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	56000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	175792000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	21376000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	21376000	USD
CY2015Q3	us-gaap	Revenues Revenues	19972000	USD
CY2015Q4	us-gaap	Revenues Revenues	18035000	USD
CY2015Q2	us-gaap	Costs And Expenses CostsAndExpenses	11102000	USD
CY2015Q3	us-gaap	Costs And Expenses CostsAndExpenses	11521000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	8414000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	8451000	USD
CY2015Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	6268000	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	3571000	USD
CY2015Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	4559000	USD
CY2015Q4	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	2876000	USD
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.40
CY2015Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.25
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.39
CY2015Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.25
CY2014	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	784000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	19448000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	70967000	USD
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	21400000	USD
CY2016	us-gaap	Fair Value Inputs Discount Rate FairValueInputsDiscountRate	0.15	pure
CY2016Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	0	USD
CY2015Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	0	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	200000	shares
CY2016	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	81000	USD
CY2014	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	70000	USD
CY2015	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	74000	USD
CY2016Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	2398000	USD
CY2015Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	31535000	USD
CY2015Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	13586000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1666667	shares
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1666667	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3423000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3856000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6067000	USD
CY2014	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	46680000	USD
CY2014	anip	Embedded Derivative Bifurcated Amount Reclassified To Stockholders Equity Net Of Deferred Tax Asset Liability EmbeddedDerivativeBifurcatedAmountReclassifiedToStockholdersEquityNetOfDeferredTaxAssetLiability	20195000	USD
CY2014	anip	Net Adjustments To Additional Paid In Capital Bond Hedge Acquired Warrant Issued Net Of Deferred Tax Asset Liability NetAdjustmentsToAdditionalPaidInCapitalBondHedgeAcquiredWarrantIssuedNetOfDeferredTaxAssetLiability	-2575000	USD
CY2014	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	750000	USD
CY2014	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2015	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2016	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	617000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	360000	USD
CY2016	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	2500000	USD
CY2016	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-8911000	USD
CY2015	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-1877000	USD
CY2014	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-14459000	USD
CY2016	us-gaap	Proceeds From Repurchase Of Equity ProceedsFromRepurchaseOfEquity	0	USD
CY2015	us-gaap	Proceeds From Repurchase Of Equity ProceedsFromRepurchaseOfEquity	0	USD
CY2014	us-gaap	Proceeds From Repurchase Of Equity ProceedsFromRepurchaseOfEquity	46680000	USD
CY2016	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2015	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2014	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	138243000	USD
CY2016	us-gaap	Payments For Proceeds From Derivative Instrument Financing Activities PaymentsForProceedsFromDerivativeInstrumentFinancingActivities	0	USD
CY2015	us-gaap	Payments For Proceeds From Derivative Instrument Financing Activities PaymentsForProceedsFromDerivativeInstrumentFinancingActivities	0	USD
CY2014	us-gaap	Payments For Proceeds From Derivative Instrument Financing Activities PaymentsForProceedsFromDerivativeInstrumentFinancingActivities	15623000	USD
CY2016	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">Organization and Business</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">ANI Pharmaceuticals, Inc. and its consolidated subsidiaries (together, “ANI,” the “Company,” “we,” “us,” or “our”) is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. ANI was organized as a Delaware corporation in April 2001. At our two facilities located in Baudette, Minnesota, we manufacture oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. We also perform contract manufacturing for other pharmaceutical companies.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On June 19, 2013, BioSante Pharmaceuticals, Inc. (“BioSante”) acquired ANIP Acquisition Company (“ANIP”) in an all-stock, tax-free reorganization (the “Merger”), in which ANIP became a wholly-owned subsidiary of BioSante. BioSante was renamed ANI Pharmaceuticals, Inc. The Merger was accounted for as a reverse acquisition pursuant to which ANIP was considered the acquiring entity for accounting purposes. As such, ANIP's historical results of operations replace BioSante's historical results of operations for all periods prior to the Merger. The results of operations of both companies are included in our consolidated financial statements for all periods after completion of the Merger.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Our operations are subject to certain risks and uncertainties including, among others, current and potential competitors with greater resources, dependence on significant customers, lack of operating history and uncertainty of future profitability, and possible fluctuations in financial results. The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the ordinary course of business. The propriety of using the going-concern basis is dependent upon, among other things, the achievement of future profitable operations, the ability to generate sufficient cash from operations, and potential other funding sources, including cash on hand, to meet our obligations as they become due. We believe the going-concern basis is appropriate for the accompanying consolidated financial statements based on our current operating plan and business strategy for the 12 months following the issuance of this report.</font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt -0.25in"> <strong><font style="FONT-SIZE: 10pt">Use of Estimates</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not limited to, stock-based compensation, allowance for doubtful accounts, accruals for chargebacks, administrative fees and rebates, government rebates, returns and other allowances, allowance for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, fair value of long-lived assets, deferred taxes and valuation allowance, purchase price allocations, and the depreciable lives of long-lived assets. Because of the uncertainties inherent in such estimates, actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">Credit Concentration</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Our customers are primarily wholesale distributors, chain drug stores, group purchasing organizations, and other pharmaceutical companies.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">During the year ended December 31, 2016, three customers represented approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 28</font>%, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 22</font>%, and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 18</font>% of net revenues, respectively. As of December 31, 2016, accounts receivable from these customers totaled <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 83</font>% of net accounts receivable. During the year ended December 31, 2015, three customers represented approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 26</font>%, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 20</font>%, and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 18</font>% of net revenues, respectively. During the year ended December 31, 2014, three customers represented approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 30</font>%, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25</font>%, and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 14</font>% of net revenues, respectively.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q4	anip	Fdic Guaranteed Amount FdicGuaranteedAmount	250000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	5666000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	5194000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	7921000	USD
CY2016Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	1298000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	1346000	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	1125000	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	2543000	USD
CY2016Q4	anip	Chargebacks And Other Accruals As Percent Of Gross Revenue ChargebacksAndOtherAccrualsAsPercentOfGrossRevenue	0.5	pure
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	819000	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	819000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	99000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	97000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	66000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	68000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	19000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	349000	USD
CY2016Q1	us-gaap	Revenues Revenues	20555000	USD
CY2016Q2	us-gaap	Revenues Revenues	31337000	USD
CY2016Q3	us-gaap	Revenues Revenues	38525000	USD
CY2016Q4	us-gaap	Revenues Revenues	38205000	USD
CY2016Q1	us-gaap	Costs And Expenses CostsAndExpenses	14889000	USD
CY2016Q2	us-gaap	Costs And Expenses CostsAndExpenses	26143000	USD
CY2016Q3	us-gaap	Costs And Expenses CostsAndExpenses	30604000	USD
CY2016Q4	us-gaap	Costs And Expenses CostsAndExpenses	36907000	USD
CY2016Q4	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1080000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.12
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.10
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.22
CY2016Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.12
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.10
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.22
CY2016Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2015Q1	us-gaap	Revenues Revenues	18799000	USD
CY2015Q2	us-gaap	Revenues Revenues	19516000	USD
CY2015Q1	us-gaap	Costs And Expenses CostsAndExpenses	9232000	USD
CY2015Q4	us-gaap	Costs And Expenses CostsAndExpenses	11767000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	9567000	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	4369000	USD
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.38
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.31
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.38
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.31
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6100000	USD
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3900000	USD
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3400000	USD
CY2016Q4	us-gaap	Long Term Debt Percentage Bearing Fixed Interest Rate LongTermDebtPercentageBearingFixedInterestRate	0.030	pure
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4500000	shares
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4500000	shares
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4700000	shares
CY2016	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	3934000	USD
CY2015	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	15375000	USD
CY2014	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	28747000	USD
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	3913000	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	15290000	USD
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	28588000	USD
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	3913000	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	15291000	USD
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	28589000	USD
CY2016	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	11717000	USD
CY2015	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	7264000	USD
CY2014	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	4034000	USD
CY2016	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1321000	USD
CY2015	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	611000	USD
CY2014	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	273000	USD
CY2016	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	13038000	USD
CY2015	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	7875000	USD
CY2014	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	4307000	USD
CY2016	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-8387000	USD
CY2015	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1468000	USD
CY2014	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	2113000	USD
CY2016	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-658000	USD
CY2015	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-409000	USD
CY2014	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	154000	USD
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-9045000	USD
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1877000	USD
CY2014	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	2267000	USD
CY2016	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-134000	USD
CY2015	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	0	USD
CY2014	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	16726000	USD
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.021	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.021	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.010	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities	0.144	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities	0.053	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities	-0	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.016	pure
CY2015Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	16000	USD
CY2016Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	8890000	USD
CY2015Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	13872000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	275000	USD
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.865	pure
CY2016	anip	Effective Income Tax Rate Reconciliation Share Based Compensation Cost With Windfall Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationCostWithWindfallTaxBenefitPercent	0	pure
CY2015	anip	Effective Income Tax Rate Reconciliation Share Based Compensation Cost With Windfall Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationCostWithWindfallTaxBenefitPercent	-0.001	pure
CY2014	anip	Effective Income Tax Rate Reconciliation Share Based Compensation Cost With Windfall Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationCostWithWindfallTaxBenefitPercent	-0.012	pure
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.547	pure
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.293	pure
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.484	pure
CY2016	anip	Effective Income Tax Rate Reconciliation Nondeductible Expense Foreign Expenses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseForeignExpenses	0.233	pure
CY2015	anip	Effective Income Tax Rate Reconciliation Nondeductible Expense Foreign Expenses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseForeignExpenses	0	pure
CY2014	anip	Effective Income Tax Rate Reconciliation Nondeductible Expense Foreign Expenses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseForeignExpenses	0	pure
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	3002000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2153000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Hedging Transactions DeferredTaxAssetsHedgingTransactions	10921000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Hedging Transactions DeferredTaxAssetsHedgingTransactions	12243000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	7137000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	2945000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	1255000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	1271000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	6302000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	3631000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5095000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7938000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1680000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1149000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	35392000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	31330000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	857000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	700000	USD
CY2016Q4	anip	Deferred Tax Liabilities Debt Discount DeferredTaxLiabilitiesDebtDiscount	7664000	USD
CY2015Q4	anip	Deferred Tax Liabilities Debt Discount DeferredTaxLiabilitiesDebtDiscount	10029000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	353000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	3127000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	16000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	142000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	26227000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	17316000	USD
CY2016Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	13700000	USD
CY2016	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	approximately $0.8 million per year.
CY2015Q4	us-gaap	Inventory Gross InventoryGross	13543000	USD
CY2016Q4	us-gaap	Inventory Gross InventoryGross	26357000	USD
CY2015	us-gaap	Interest Expense Debt InterestExpenseDebt	11143000	USD
CY2016	us-gaap	Interest Expense Debt InterestExpenseDebt	11294000	USD
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2016Q4	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.079	pure
CY2015Q4	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.078	pure
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	16385000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11581000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	203992000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	76498000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	28200000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	10101000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	21731000	USD
CY2016	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	1000000	USD
CY2015	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	400000	USD
CY2014	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	600000	USD
CY2016Q4	anip	Accrued Royalties Related To Asset Purchase AccruedRoyaltiesRelatedToAssetPurchase	3882000	USD
CY2015Q4	anip	Accrued Royalties Related To Asset Purchase AccruedRoyaltiesRelatedToAssetPurchase	0	USD
CY2014Q4	anip	Accrued Royalties Related To Asset Purchase AccruedRoyaltiesRelatedToAssetPurchase	0	USD
CY2016	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1570000	USD
CY2016	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2015	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2014	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	750000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	40962000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	139785000	USD
CY2016	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	6685000	USD
CY2015	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2014	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2016	anip	Increase Decrease In Returned Goods Reserve IncreaseDecreaseInReturnedGoodsReserve	3108000	USD
CY2015	anip	Increase Decrease In Returned Goods Reserve IncreaseDecreaseInReturnedGoodsReserve	1203000	USD
CY2014	anip	Increase Decrease In Returned Goods Reserve IncreaseDecreaseInReturnedGoodsReserve	709000	USD
CY2016	us-gaap	Interest Paid Net InterestPaidNet	4078000	USD
CY2015	us-gaap	Interest Paid Net InterestPaidNet	4149000	USD
CY2014	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2016	anip	Increase Decrease Accrued Government Rebates IncreaseDecreaseAccruedGovernmentRebates	1260000	USD
CY2015	anip	Increase Decrease Accrued Government Rebates IncreaseDecreaseAccruedGovernmentRebates	2367000	USD
CY2014	anip	Increase Decrease Accrued Government Rebates IncreaseDecreaseAccruedGovernmentRebates	2011000	USD
CY2016Q4	anip	Accrued Government Rebates AccruedGovernmentRebates	5891000	USD
CY2015Q4	anip	Accrued Government Rebates AccruedGovernmentRebates	4631000	USD
CY2015	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	113000	USD
CY2016	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	122000	USD
CY2016	anip	Effective Income Tax Rate Reconciliation Share Based Compensation Cost No Windfall Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationCostNoWindfallTaxBenefitPercent	0.057	pure
CY2015	anip	Effective Income Tax Rate Reconciliation Share Based Compensation Cost No Windfall Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationCostNoWindfallTaxBenefitPercent	0.011	pure
CY2014	anip	Effective Income Tax Rate Reconciliation Share Based Compensation Cost No Windfall Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationCostNoWindfallTaxBenefitPercent	0.047	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.014	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.035	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.014	pure

Files In Submission

Name	View Source	Status
0001144204-17-012507-index-headers.html	Edgar Link	pending
0001144204-17-012507-index.html	Edgar Link	pending
0001144204-17-012507.txt	Edgar Link	pending
0001144204-17-012507-xbrl.zip	Edgar Link	pending
anip-20161231.xml	Edgar Link	completed
anip-20161231.xsd	Edgar Link	pending
anip-20161231_cal.xml	Edgar Link	unprocessable
anip-20161231_def.xml	Edgar Link	unprocessable
anip-20161231_lab.xml	Edgar Link	unprocessable
anip-20161231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pg40img1_10k.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v458397_10k.htm	Edgar Link	pending
v458397_ex21.htm	Edgar Link	pending
v458397_ex23-1.htm	Edgar Link	pending
v458397_ex31-1.htm	Edgar Link	pending
v458397_ex31-2.htm	Edgar Link	pending
v458397_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ANIP
ANI PHARMACEUTICALS INC Stock $anip

2015 Q4 Form 10-K Financial Statement

#000114420417012507 Filed on March 02, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANIP ANI PHARMACEUTICALS INC Stock $anip

2015 Q4 Form 10-K Financial Statement

#000114420417012507 Filed on March 02, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANIP
ANI PHARMACEUTICALS INC Stock $anip